ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Nichi-Iko Pharmaceutical Co., Ltd.

  • 1,855.00 JPY
  • -32.00
  • -1.70%
  • Japan
    Dec 14, 2018
  • Ticker
  • Prev. close
  • Market cap (JPY)
  • Market cap (USD)
  • Shares

Business Summary

Nichi-Iko Pharmaceutical Co., Ltd. develops, manufactures, and markets generic pharmaceutical products. Its products are classified into Prescriptive and General Over-the-Counter (OTC) drugs. These products are used for the treatment of circulatory, digestive, respiratory, central and peripheral nervous systems problems. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.

Financial Highlights

Mar 2018 JPYUSD
Gross Profit40,803M368.15M
Operating income13,200M119.09M
Income before tax9,067M81.80M
Net income8,069M72.80M
Diluted EPS142.921.28
Dividends Per Share300.27
Total Assets278,364M2,617.43M
Total liabilities190,819M1,794.25M
Total equity87,542M823.14M
Operating cash flow18,925M170.75M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 103,622M 127,021M 143,513M 149,263M 164,717M
Gross Profit 39,449M 46,876M 53,313M 37,611M 40,803M
Operating income 7,383M 9,619M 12,910M 10,026M 13,200M
Income before tax 7,055M 9,488M 15,359M 5,963M 9,067M
Net income 4,588M 6,592M 11,031M 4,796M 8,069M
EBITDA 13,406M 20,265M 24,200M 17,091M 22,179M
Diluted EPS 81.47 110.13 184.01 84.08 142.92
Dividends Per Share 24.75 26.60 30 30 30
Total Assets 129,130M 139,834M 161,128M 268,900M 278,364M
Total liabilities 62,935M 65,347M 78,531M 185,725M 190,819M
Total equity 66,195M 74,487M 82,597M 83,171M 87,542M
Operating cash flow 5,546M 21,179M 7,097M -4,076M 18,925M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,034.44M 1,156.24M 1,195.10M 1,378.39M 1,486.18M
Gross Profit 393.81M 426.70M 443.96M 347.32M 368.15M
Operating income 73.70M 87.55M 107.50M 92.58M 119.09M
Income before tax 70.42M 86.36M 127.90M 55.06M 81.80M
Net income 45.80M 60.00M 91.86M 44.28M 72.80M
EBITDA 133.83M 184.46M 201.52M 157.82M 200.11M
Diluted EPS 0.81 1.00 1.53 0.77 1.28
Dividends Per Share 0.24 0.24 0.24 0.27 0.27
Total Assets 1,253.87M 1,166.01M 1,433.58M 2,413.17M 2,617.43M
Total liabilities 611.10M 544.89M 698.70M 1,666.74M 1,794.25M
Total equity 642.76M 621.11M 734.88M 746.39M 823.14M
Operating cash flow 55.36M 192.78M 59.10M -37.64M 170.75M

Valuation Measures

Mar 2018
Operating margin8.01%
Profit margin4.89%

Key executives

  • President & Representative Director: Yuichi Tamura
  • Director, Senior Head-Compliance & Internal Audit: Kenji Akane
  • Director & General Manager-Administration: Noboru Inasaka
  • Director & Managing Executive Officer: Takahiro Yoshikawa
  • Auditor: Yoshihito Sugi


  • Hokuhoku Financial Group, Inc. (4.4%)
  • Nipro Corp. (2.0%)
  • The Vanguard Group, Inc. (1.8%)
  • Nichi-Iko Pharmaceutical Co., Ltd. (1.5%)
  • Nomura Asset Management Co., Ltd. (1.4%)
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.2%)
  • Medipal Holdings Corp. (1.1%)
  • Dimensional Fund Advisors LP (1.1%)
  • Nichi-Iko Pharmaceutical Employee Incentive Plan (0.9%)

Contact Details

Related Companies

  • Nichi Iko Pharmaceutical Trust
  • Astellas Pharma Tech Co., Ltd. /Fuji Plant Bus/
  • Nichi-Iko Pharmaceutical Employee Incentive Plan
  • Nichiiko Pharma KK
  • Nichiiko Osaka KK
  • Yakuhan Pharmaceutical Co., Ltd.
  • Sagent Pharmaceuticals, Inc.
  • Kobayashi Pharmaceutical Industries Co. Ltd.
  • Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
  • Oriental Pharmaceutical Co., Ltd.
  • Teikoku Medix Co., Ltd.
  • Japan Galen, Inc.
  • Maruko Pharmaceutical Co. Ltd.
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan


  • Hikma Pharmaceuticals Plc
  • Spectrum Pharmaceuticals, Inc.
  • Amphastar Pharmaceuticals Inc
Last Updated on 14 Dec, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media